肝OATP基質薬及び内在性基質の生理学的速度論モデル構築に基づいた薬物相互作用予測法の開発

DOI Web Site Web Site 参考文献19件
  • 吉門 崇
    横浜薬科大学薬学部臨床薬理学研究室

書誌事項

タイトル別名
  • Development of Prediction Methods for Drug–Drug Interactions Based on the Construction of Physiologically Based Pharmacokinetic Models for Hepatic OATP Substrate Drugs and Endogenous Substrates
  • カン OATPキシツヤク オヨビ ナイザイセイキシツ ノ セイリガクテキ ソクドロン モデル コウチク ニ モトズイタ ヤクブツ ソウゴ サヨウ ヨソクホウ ノ カイハツ

この論文をさがす

抄録

<p>Quantitative prediction of the potential for drug–drug interaction (DDI) is essential to guarantee the safety and efficacy of drugs. DDI screening, modeling, and prediction is standard practice in the pharmaceutical industry. This review describes our work on (1) the establishment of a standard framework for determining physiologically based pharmacokinetic (PBPK) model structures and parameters useful for quantitatively analyzing DDIs via hepatic organic anion transporting polypeptides (OATPs). By analyzing clinically observed DDIs involving several statins as substrates, and cyclosporin A and rifampicin as inhibitors, similar in vivo inhibition constants for OATPs by each inhibitor were obtained, regardless of the substrate. (2) We took a PBPK modeling-based approach to define rate-determining processes in hepatic elimination of several OATPs and CYP3A dual substrates using our clinical DDI data with specific inhibitors for OATPs and CYP3A. Essential in vivo parameters (the passive diffusion/active transport ratio in the uptake, and the fraction of intrinsic clearance in the total drug elimination from the hepatocytes) dominating the rate-determining process in hepatic elimination were estimated quantitatively. (3) Finally, using our clinical DDI data with rifampicin, we established a PBPK model for coproporphyrin I (CP-I), which is expected to act as an endogenous substrate (biomarker) supporting the prediction of DDI involving hepatic OATPs. Our PBPK modeling-based approach with several in vitro experiments using CP-I and OATP probe substrates (statins) demonstrated the usefulness of the translation of the effect of an OATP inhibitor on CP-I pharmacokinetics into that on OATP probe substrates in drug discovery and development.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 143 (1), 11-19, 2023-01-01

    公益社団法人 日本薬学会

参考文献 (19)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ